Literature DB >> 2423519

Acute effect of 5-fluorouracil on cytoplasmic and nuclear dihydrofolate reductase messenger RNA metabolism.

R D Armstrong, M Lewis, S G Stern, E C Cadman.   

Abstract

Studies were completed in C3-L5178Y cells, in which the DNA-coding region for dihydrofolate reductase messenger RNA (DHFR-mRNA) is amplified, to determine the acute effect of 5-fluorouracil (FUra) on DHFR-mRNA metabolism. There was minimal to no effect of 100 microM FUra on total cytoplasmic DHFR-mRNA levels by 6 and 12 h and only a 25% reduction by 24 h. These results contrasted with the nuclear DHFR-mRNA levels which by 6 h following exposure to FUra increased by 80% in a dose-dependent manner. Furthermore, some of the increased nuclear DHFR-mRNA was found to be in a non-polyadenylated form. Under conditions to examine only RNA synthesized during the drug exposure, FUra was found to markedly enhance the level of newly synthesized nuclear DHFR-mRNA in a dose-dependent manner, while also producing an apparent dose-dependent reduction in the cytoplasmic DHFR-mRNA. RNA fractionated by 1.5% agarose-urea gel electrophoresis revealed two major cytoplasmic DHFR-mRNA species approximately 1.8 and 0.8 kilobases in size. Following a 24-h FUra exposure, a dose-dependent loss of the 0.8-kilobase DHFR-mRNA was observed. The combined results of these experiments indicate that FUra treatment reduces the ability of nascent DHFR-mRNA to relocate to the cytoplasm, suggesting either an inhibition of mRNA processing or nuclear-cytoplasmic transport.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423519

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Use of adenoviral vectors to target chemotherapy to tumor vascular endothelial cells suppresses growth of breast cancer and melanoma.

Authors:  Pingchuan Li; Yanzheng Liu; Jonathan Maynard; Yucheng Tang; Albert Deisseroth
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  RNA polymerase II transcripts as targets for 5-fluorouridine cytotoxicity: antagonism of 5-fluorouridine actions by alpha-amanitin.

Authors:  R Heimer; A C Sartorelli
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.

Authors:  J L Grem
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

4.  Topical Chemotherapy for Treating Ocular Surface Squamous Neoplasia with a Combination of Interferon α-2b and 5-Fluorouracil.

Authors:  Wen Geng; Jia-Song Wang; Bing-Jie Shi; Hua-Tao Xie; Ming-Chang Zhang
Journal:  Ophthalmol Ther       Date:  2022-06-15

5.  Interactions of transfer RNA pseudouridine synthases with RNAs substituted with fluorouracil.

Authors:  T Samuelsson
Journal:  Nucleic Acids Res       Date:  1991-11-25       Impact factor: 16.971

Review 6.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

7.  Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivo.

Authors:  Xinliang Zhao; Yi-Tao Yu
Journal:  Nucleic Acids Res       Date:  2006-12-14       Impact factor: 16.971

8.  Roles Of EAAT1, DHFR, And Fetuin-A In The Pathogenesis, Progression And Prognosis Of Chondrosarcoma.

Authors:  Lile He; Xiangyu Shi; Zhongyue Liu; Xiaolei Ren; Chenghao Zhang; Zhulin Yang; Zhihong Li
Journal:  Onco Targets Ther       Date:  2019-10-14       Impact factor: 4.147

9.  Downregulation of KRAB zinc finger proteins in 5-fluorouracil resistant colorectal cancer cells.

Authors:  Anaïs Chauvin; Danny Bergeron; Jean Vencic; Dominique Lévesque; Benoit Paquette; Michelle S Scott; François-Michel Boisvert
Journal:  BMC Cancer       Date:  2022-04-04       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.